TABLE 2

Population pharmacokinetic parameters of tenofovir from final modela

ParameterEstimate (RSE%)Bootstrap median (95% CI)
ΘCL (liters/h)47.8 (2.5)47 (43.4–49.7)
ΘVC (liters)214 (16)211 (179–381)
ΘCRCL0.15 (32)0.16 (0.15–0.18)
ΘKa (liters/h)1.7 (15)1.5 (0.85–2.02)
ΘQ (liters/h)300 (21)289 (245–485)
ΘVP (liters)512 (7)490 (374–557)
ΘALAG1 (h)0.69 (15)0.69 (0.5–0.8)
IIV on CL22.6 (15)22.4 (16.3–26.5)
IIV on Vc76 (22)81.7 (51.8–88.8)
IIV on Ka79 (12)80 (45–89)
IIV on F110 (fixed)10 (fixed)
IIV on additive (ng/ml)150 (14)127 (87–160)
Residual variability
    Additive error 1 (ng/ml)19 (13)15.8 (4.7–16.3)
    Additive error 2 (ng/ml)0.14 (27)0.16 (0.15–0.18)
    Proportional error (% CV)21 (7)21 (19.5–27.9)
  • a ΘCL, clearance; ΘVC, volume of central compartment; ΘCRCL, effect of CLCR on clearance; ΘKa, absorption rate constant; ΘALAG1, absorption lag time; IIV, interindividual variability; F1, bioavailability fraction in the model; CV, coefficient of variation. Additive error 1 is the additive error for the Partners PrEP Study; additive error 2 is the additive error for the Partners Demonstration Project.